ReviewWorld journal of nephrology2015
Lipid abnormalities in kidney disease and management strategies.
Review in World journal of nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- The Use of Curcumin for the Treatment of Renal Disorders: A Systematic Review of Randomized Controlled Trials.Advances in experimental medicine and biology · 2021Pooled it
- Simvastatin Mitigates Kidney Injury via Inhibition of the TNF-α/α-SMA Signaling Pathway in a Subtotal Nephrectomy Model.Journal of experimental pharmacology · 2026Article
- Exploring the Interplay Between Kidney Dysfunction and Cardiovascular Disease.Medical sciences (Basel, Switzerland) · 2025Review
- Association between epicardial and pericadial fat thickness and coronary artery calcification severity in chronic kidney disease patients: A pilot study.ARYA atherosclerosis · 2025Article
- Novel insights and an updated review of metabolic syndrome in immune-mediated organ transplant rejection.Frontiers in immunology · 2025Review
- The Association of Niacin Use with Kidney Outcomes and Mortality.American journal of nephrology · 2025Article
- Understanding Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Therapeutic Implications.International journal of molecular sciences · 2024Review
- Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.International journal of molecular sciences · 2023Review
- Review
- The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy.Circulation research · 2023Review
- Review of Isoflavones and Their Potential Clinical Impacts on Cardiovascular and Bone Metabolism Markers in Peritoneal Dialysis Patients.Preventive nutrition and food science · 2022Review
- Association between urinary sodium excretion and hard outcomes in non-dialysis chronic kidney disease patients.BMC nephrology · 2022Article
- The Effect of Sumac Fruit on Serum Lipids and Body Mass Index in Hemodialysis Patients.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Article
- Mass Spectrometry-Based Lipidomics Reveals Differential Changes in the Accumulated Lipid Classes in Chronic Kidney Disease.Metabolites · 2021Article
- Secondary dyslipidemia: its treatments and association with atherosclerosis.Global health & medicine · 2021Review
- Hyperlipidemia and mortality associated with diabetes mellitus co-existence in Chinese peritoneal dialysis patients.Lipids in health and disease · 2020Article
- Characteristics of patients at initiation of renal replacement therapy - experience of a hemodialysis center.Experimental and therapeutic medicine · 2020Article
- The predictive study of the relation between elevated low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality in peritoneal dialysis.Lipids in health and disease · 2020Article
- Innovatively Established Analysis Method for Lipoprotein Profiles Based on High-Performance Anion-Exchange Liquid Chromatography.Journal of atherosclerosis and thrombosis · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with kidney diseases continue to experience significant cardiovascular disease (CVD) morbidity and mortality. Although there are many important risk factors playing a role in the pathogenesis of CVD in chronic kidney disease (CKD) patients, dyslipidemia (elevated triglycerides, elevated oxidized low-density lipoprotein and low/dysfunctional low high-density) represents one of the modifiable risk factors. Renal failure patients have unique lipid abnormalities which not only have complex role in pathogenesis of CVD but also cause relative resistance to usual interventions. Most of the randomized trials have been in hemodialysis population and data from CKD non-dialysis, peritoneal dialysis and renal transplant populations is extremely limited. Compared to general population, evidence of mortality benefit of lipid lowering medications in CKD population is scarce. Future research should be directed towards establishing long term benefits and side effects of lipid lowering medications, through randomized trials, in CKD population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.